Oncolytics prioritizes SCAC and CRC registration studies; GOBLET enrollment closed

ONCOLYTICS BIOTECH INC

Concluded enrollment in GOBLET gastrointestinal study; now focusing on registrational studies in squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC).
Plans to meet with FDA mid-April to align on single-arm SCAC registrational study; believes <100 subjects may be sufficient for approval.
GOBLET Cohort 5 (PDAC) enrollment stopped at ~20 patients per arm; data to inform future PDAC strategy.
Sufficient cash on hand to execute near-term milestones, avoiding immediate material dilution.
GOBLET data support platform approach in GI cancers; company will follow existing Cohort 5 patients for survival data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.